Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FCSC Fibrocell Science (FCSC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Fibrocell Science Stock (NASDAQ:FCSC) 30 days 90 days 365 days Advanced Chart Ad Wide Moat ResearchFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most important financial story of the decade. Goldman Sachs, the IMF, JP Morgan, Bank of America, and Morgan Stanley have issued warnings. Yet most ordinary Americans have no idea. Now one former Trump advisor is sounding the alarm. “If people knew the full facts, there’d be blood in the streets.” Get the facts and learn how to protect your family now. Get Fibrocell Science alerts:Sign Up Key Stats Today's Range$3.00▼$3.0050-Day Range$3.00▼$3.0052-Week Range$1.45▼$3.28VolumeN/AAverage Volume78,673 shsMarket Capitalization$29.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewFibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.Read More… Former Trump advisor releases terrifying warning (Ad)Goldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most important financial story of the decade. Goldman Sachs, the IMF, JP Morgan, Bank of America, and Morgan Stanley have issued warnings. Yet most ordinary Americans have no idea. Now one former Trump advisor is sounding the alarm. “If people knew the full facts, there’d be blood in the streets.” Get the facts and learn how to protect your family now. Receive FCSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fibrocell Science and its competitors with MarketBeat's FREE daily newsletter. Email Address FCSC Stock News HeadlinesBest Data Science Bootcamps Online In 2024February 20, 2024 | forbes.comScience & Tech NewsFebruary 6, 2024 | dailymail.co.ukFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most important financial story of the decade. Goldman Sachs, the IMF, JP Morgan, Bank of America, and Morgan Stanley have issued warnings. Yet most ordinary Americans have no idea. Now one former Trump advisor is sounding the alarm. “If people knew the full facts, there’d be blood in the streets.” November 24, 2024 | Wide Moat Research (Ad)What You Need to Know About Becoming a Computer Science MajorSeptember 16, 2023 | usnews.comEpidermolysis Bullosa Therapeutics Market Factual Overview Research Report 2023-2030April 7, 2023 | marketwatch.comOramed PharmaceuticalsJanuary 13, 2023 | forbes.comFibrocell Science (FCSC) Stock Spikes Following Rare Pediatric Disease Treatment DesignationDecember 27, 2022 | thestreet.comSee More Headlines FCSC Stock Analysis - Frequently Asked Questions How were Fibrocell Science's earnings last quarter? Fibrocell Science Inc (NASDAQ:FCSC) released its quarterly earnings results on Wednesday, August, 14th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $1.30. The business had revenue of $21.79 million for the quarter. When did Fibrocell Science's stock split? Fibrocell Science shares reverse split on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Fibrocell Science own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fibrocell Science investors own include The Carlyle Group (CG), Celldex Therapeutics (CLDX), Neos Therapeutics (NEOS), Amarin (AMRN), OPKO Health (OPK), Neurotrope (NTRP) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings8/14/2019Today11/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FCSC CUSIPN/A CIK357097 Webfibrocell.com Phone484-713-6000FaxN/AEmployees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E Ratio30.00 P/E GrowthN/ANet Income$-10,280,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity23.10% Return on Assets10.56% Debt Debt-to-Equity Ratio0.47 Current Ratio5.09 Quick Ratio5.09 Sales & Book Value Annual Sales$350,000.00 Price / Sales83.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book3.06Miscellaneous Outstanding Shares9,760,000Free FloatN/AMarket Cap$29.28 million OptionableOptionable Beta1.67 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:FCSC) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersThe #1 ETF for monthly incomeWe just found the #1 ETF for monthly income. This outlier is paying a huge 22% dividend... And you could...Investors Alley | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fibrocell Science Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fibrocell Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.